The Response of the Urinary Microbiome to Botox.

Autor: Palm KM; Division of Female Pelvic Medicine and Reconstructive Surgery, Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA. Kasey.m.roberts@gmail.com., Abrams MK; Division of Female Pelvic Medicine and Reconstructive Surgery, Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA., Sears SB; Division of Female Pelvic Medicine and Reconstructive Surgery, Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA., Wherley SD; Division of Female Pelvic Medicine and Reconstructive Surgery, Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA., Alfahmy AM; Division of Female Pelvic Medicine and Reconstructive Surgery, Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA., Kamumbu SA; Case Western Reserve University School of Medicine, Cleveland, OH, USA., Chakraborty NN; Division of Female Pelvic Medicine and Reconstructive Surgery, Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA., Mahajan ST; Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA., El-Nashar SA; Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA., Henderson JW; Division of Female Pelvic Medicine and Reconstructive Surgery, Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA., Hijaz AK; Division of Female Pelvic Medicine and Reconstructive Surgery, Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA., Mangel JM; Division of Female Pelvic Medicine and Reconstructive Surgery, MetroHealth Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA., Pollard RR; Division of Female Pelvic Medicine and Reconstructive Surgery, MetroHealth Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA., Al-Shakhshir H; Center for Medical Mycology, Department of Dermatology, Case Western Reserve University, Cleveland, OH, USA., Retuerto MA; Center for Medical Mycology, Department of Dermatology, Case Western Reserve University, Cleveland, OH, USA., Steller KM; Center for Medical Mycology, Department of Dermatology, Case Western Reserve University, Cleveland, OH, USA., Elshaer M; Clinical Pathology Department, Mansoura Faculty of Medicine, Mansoura, Egypt., Ghannoum MA; Center for Medical Mycology, Department of Dermatology, Case Western Reserve University, Cleveland, OH, USA., Sheyn D; Division of Female Pelvic Medicine and Reconstructive Surgery, Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Jazyk: angličtina
Zdroj: International urogynecology journal [Int Urogynecol J] 2024 Jan; Vol. 35 (1), pp. 237-251. Date of Electronic Publication: 2024 Jan 02.
DOI: 10.1007/s00192-023-05703-1
Abstrakt: Introduction and Hypothesis: Our objective was to evaluate if botox alters the urinary microbiome of patients with overactive bladder and whether this alteration is predictive of treatment response.
Methods: This multicenter prospective cohort study included 18-89-year-old patients undergoing treatment for overactive bladder with 100 units of botox. Urine samples were collected by straight catheterization on the day of the procedure (S1) and again 4 weeks later (S2). Participants completed the Patient Global Impression of Improvement form at their second visit for dichotomization into responders and nonresponders. The microbiome was sequenced using 16s rRNA sequencing. Wilcoxon signed rank and Wilcoxon rank sum were used to compare the microbiome, whereas chi-square, Wilcoxon rank sum, and the independent t-test were utilized for clinical data.
Results: Sixty-eight participants were included in the analysis. The mean relative abundance and prevalence of Beauveria bassiana, Xerocomus chrysenteron, Crinipellis zonata, and Micrococcus luteus were all found to increase between S1 and S2 in responders; whereas in nonresponders the mean relative abundance and prevalence of Pseudomonas fragi were found to decrease. The MRA and prevalence of Weissella cibaria, Acinetobacter johnsonii, and Acinetobacter schindleri were found to be greater in responders than nonresponders at the time of S1. Significant UM differences in the S1 of patients who did (n = 5) and did not go on to develop a post-treatment UTI were noted.
Conclusions: Longitudinal urobiome differences may exist between patients who do and do not respond to botox.
(© 2024. The International Urogynecological Association.)
Databáze: MEDLINE
Externí odkaz: